Status:
UNKNOWN
Controlled Low Central Venous Pressure Combined With Hilar Block in Laparoscopic Hepatectomy
Lead Sponsor:
Sun Yat-sen University
Conditions:
Laparoscopic Hepatectomy
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Hepatectomy is the preferred method for the treatment of liver tumors. Since the liver is a double blood supply organ, massive hemorrhage during hepatectomy may lead to hemodynamic instability, prolon...
Eligibility Criteria
Inclusion
- clinical diagnosis or pathological diagnosis of hepatocellular carcinoma;
- resectable non-left lobes, left and right liver lesions, and the resection range is expected to be greater than or equal to 1 liver segment, no non-cancerous thrombus; Indocyanine Green Retention Rate (ICGR) 15 minutes retention rate \<10%
- did not receive systemic chemotherapy or other targeted drug therapy for diagnosing hepatocellular carcinoma(HCC) before participating in the study;
- generally good, Karnofsky Performance Scores (KPS) ≥ 80 points;
- Age: 18-70 years old
- Child-Pugh A level
- Baseline laboratory tests meet the following criteria:
- white blood cells ≥ 3.0 × 109 / L platelets ≥ 75 × 109 / L hemoglobin ≥ 100g / L serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) serum creatinine ≤ 1.5 x ULN International normalized ratio （INR）\<1.4, or prothrombin time \<ULN + 4 seconds albumin ≥ 30g / L Total bilirubin ≤34mmol / L
Exclusion
- patients do not agree to participate in clinical studies;
- Any of the following had been reported in the 12 months prior to participating in the study: myocardial infarction, severe / unstable angina, coronary artery bypass surgery, congestive heart failure, cerebrovascular accident (including transient ischemic attack), Pulmonary Embolism; Ongoing: corrected QT interval prolongation (≥450 ms for males and\> 470 ms for females) according to NCI-CTCAE criteria ≥2 arrhythmias;
- There are other serious acute and chronic physical or mental illnesses or laboratory abnormalities that may increase the risk associated with participating in study treatment or may interfere with the interpretation of the findings or in patients deemed inappropriate by the investigator.
Key Trial Info
Start Date :
July 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2018
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT03422913
Start Date
July 1 2017
End Date
June 30 2018
Last Update
February 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060